Recent Publications
Mitchell KA, Kluger H, Sznol M, Hartman DJ.
Ipilimumab-induced Perforating Colitis.
J Clin Gastroenterol. 2013 Apr 29.
Douglas SR, Longo WE, Narayan D.
A novel technique for perineal hernia repair.
BMJ Case Rep. 2013 Apr 10;2013
Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM.
Advances in therapy for melanoma brain metastases.
Clin Dermatol. 2013 May-Jun;31(3):264-81.
Hoang D, Sue GR, Xu F, Li P, Narayan D.
Absence of aneuploidy and gastrointestinal tumours in a man with a chromosomal 2q13 deletion and BUB1 monoallelic deficiency.
BMJ Case Rep. 2013 Feb 25;2013.
Sznol M, Chen L.
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer.
Clin Cancer Res. 2013 Mar 1;19(5):1021-34.
Chen L, Flies DB.
Molecular mechanisms of T cell co-stimulation and co-inhibition.
Nat Rev Immunol. 2013 Mar 8.
Yao S, Chen L.
Adaptive resistance: a tumor strategy to evade immune attack.
Eur J Immunol. 2013 Feb 4.
Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Mol Biol Cell. 2013 Feb 6.
Hoang D, Sue GR, Xu F, Li P, Narayan D.
Absence of aneuploidy and gastrointestinal tumours in a man with a chromosomal 2q13 deletion and BUB1 monoallelic deficiency.
BMJ Case Rep. 2013 Feb 25;2013.
Yao S, Chen L.
Adaptive resistance: a tumor strategy to evade immune attack.
Eur J Immunol. 2013 Feb 4.
Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Mol Biol Cell. 2013 Feb 6.
Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL.
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody.
Clin Cancer Res. 2013 Jan 15;19(2):462-8.
Yao S, Zhu Y, Chen L.
Advances in targeting cell surface signaling molecules for immune modulation.
Nat Rev Drug Discov. 2013 Feb 1;12(2):130-46. doi: 10.1038/nrd3877.
Dhodapkar M.
Personalized Immune-Interception of Cancer and the Battle of Two Adaptive Systems- When is the Time Right?
Cancer Prev Res (Phila). 2013 Jan 22.
Sznol JA, Jilaveanu LB, Kluger HM.
Studies of NVP-BEZ235 in Melanoma.
Curr Cancer Drug Targets. 2012 Nov 21.
Giesen E, Kluger HM., Thumar J.
Drug targets and predictive biomarkers in the management of metastatic melanoma.
Pharmgenomics Pers Med. 2012;5:139-48
Parker TL, Cooper DL, Seropian SE, Bolognia JL.
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.
Bone Marrow Transplant. 2012 Nov 19. doi: 10.1038/bmt.2012.218.
Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA.
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.
Nature. 2012 Oct 17.
Parisi F, Micsinai M, Strino F, Ariyan S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y.
Integrated analysis of tumor samples sheds light on tumor heterogeneity.
Yale J Biol Med. 2012 Sep;85(3):347-61.
Prasad S, Cody V, Saucier-Sawyer JK, Fadel TR, Edelson RL, Birchall MA, Hanlon DJ.
Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA Nanoparticles.
Pharm Res. 2012 Jul 14.
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nat Genet. 2012 Jul 29.
Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM.
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.
Nat Mater. 2012 Jul 15.
Li H, Demetris AJ, McNiff J, Matte-Martone C, Tan HS, Rothstein DM, Lakkis FG, Shlomchik WD
Profound Depletion of Host Conventional Dendritic Cells, Plasmacytoid Dendritic Cells, and B Cells Does Not Prevent Graft-versus-Host Disease Induction.
J Immunol. 2012 Mar 14.
Gao Y, Smith E, Ker E, Campbell P, Cheng EC, Zou S, Lin S, Wang L, Halene S, Krause DS.
Role of RhoA-Specific Guanine Exchange Factors in Regulation of Endomitosis in Megakaryocytes.
Dev Cell. 2012 Feb 29.
Jedrych J, Leffell D, McNiff JM.
Desmoplastic trichoepithelioma with perineural involvement: a series of seven cases.
J Cutan Pathol. 2012 Mar;39(3):317-23.
Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
PLoS One. 2012;7(2):e31331.
Broer N, Buonocore S, Goldberg C, Truini C, Faries MB, Narayan D, Ariyan S.
A proposal for the timing of management of patients with melanoma presenting during pregnancy.
J Surg Oncol. 2012 Feb 13.
Chae, W.-J. and Bothwell, A.L.M. (2011).
IL-17-mediated signaling and intestinal tumorigenesis. Drug Discovery Today: Disease Mechanisms.
Teichmann LL, Kashgarian M, Weaver CT, Roers A, Müller W, Shlomchik MJ.
B Cell-Derived IL-10 Does Not Regulate Spontaneous Systemic Autoimmunity in MRL.Faslpr Mice.
J Immunol. 2012 Jan 15;188(2):678-85.
Koduru S, Wong E, Strowig T, Sundaram R, Zhang L, Strout MP, Flavell RA, Schatz DG, Dhodapkar KM, Dhodapkar MV.
Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.
Blood. 2012 Jan 10.
Glusac EJ.
The melanoma 'epidemic': lessons from prostate cancer.
J Cutan Pathol. 2012 Jan;39(1):17-20.
McKay K, McNiff J, Subtil A.
Prominent CD56 expression by damaged and regenerating muscle fibers in the skin.
J Cutan Pathol. 2011 Dec 29.
Zito C, Kluger HM.
Immunotherapy for metastatic melanoma.
J Cell Biochem. 2011 Oct 17. doi: 10.1002/jcb.23402
Dhodapkar MV, Dhodapkar KM.
Vaccines targeting cancer stem cells: are they within reach?
Cancer J. 2011 Sep;17(5):397-402.
Kluger, H.M., Dudek, A.Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L.B., Molinaro, A., Sznol, M.
A phase 2 trial of dasatinib in advanced melanoma
(2011) Cancer, 117 (10), pp. 2202-2208. Cited 1 time.
Leong, S.P.L., Zuber, M., Ferris, R.L., Kitagawa, Y., Cabanas, R., Levenback, C., Faries, M., Saha, S.
Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients
(2011) Journal of Surgical Oncology, 103 (6), pp. 518-530.
Kluger, H.M., Hoyt, K., Bacchiocchi, A., Mayer, T., Kirsch, J., Kluger, Y., Sznol, M., Ariyan, S., Molinaro, A., Halaban, R.
Plasma markers for identifying patients with metastatic melanoma
(2011) Clinical Cancer Research, 17 (8), pp. 2417-2425.
Leong, S.P.L., Kim, J., Ross, M., Faries, M., Scoggins, C.R., Metz, W.L.R., Cope, F.O., Orahood, R.C.
A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer
(2011) Annals of Surgical Oncology, 18 (4), pp. 961-969.
Godshalk, S.E., Paranjape, T., Nallur, S., Speed, W., Chan, E., Molinaro, A.M., Bacchiocchi, A., Hoyt, K., Tworkoski, K., Stern, D.F., Sznol, M., Ariyan, S., Lazova, R., Halaban, R., Kidd, K.K., Weidhaas, J.B., Slack, F.J.
A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma
(2011) Oncogene, 30 (13), pp. 1542-1550. Cited 1 time.
